← Back to Search

Nicotinic Acetylcholine Receptor Agonist

OC-01 (varenicline 0.6mg/ml) nasal spray for Dry Eye Syndrome

Phase 3
Waitlist Available
Led By Brandon Baartman, MD
Research Sponsored by Brandon Baartman
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 2 days (48hours) post op to 7 days (1 week) post op
Awards & highlights

Summary

This trial will test the safety and effectiveness of OC-01, a varenicline nasal spray, for treating dry eye in people who have had PRK surgery.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 2 days (48hours) post op to 7 days (1 week) post op
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 2 days (48hours) post op to 7 days (1 week) post op for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire) score
Change in corneal epithelial healing

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: OC-01 (varenicline 0.6mg/ml) nasal sprayExperimental Treatment1 Intervention
Group II: Placebo (vehicle) nasal sprayPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Varenicline
FDA approved

Find a Location

Who is running the clinical trial?

Brandon BaartmanLead Sponsor
Brandon Baartman, MDPrincipal InvestigatorVance Thompson Vision
~16 spots leftby Jul 2025